Sep 26,2023

BIOCORP will exhibit at PDA – Universe of Pre-Filled Syringes and Injection Devices Conference, in Gothenburg on October 16, 17, and 18

BIOCORP announces that the team will be joining the PDA – Parenteral Drug Association – Universe of Pre-Filled Syringes and Injection Devices Conference, in Gothenburg (Sweden) on October 16, 17, and 18.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 21,2023 TOP STORY

Medtronic Diabetes announces CE Mark for new Simplera™ CGM with disposable all-in-one design

Medtronic today announced CE Mark approval for its new all-in-one, disposable Simplera continuous glucose monitor (CGM) featuring a simple, two-step insertion process. The company's newest no-fingerstick sensor does not require over tape and is seamlessly integrated with the InPen smart insulin pen, which provides real-time dosing guidance. Medtronic will begin a phased launch at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting in Hamburg, Germany on Oct. 2-6, 2023. "Despite the rapid adoption of CGM over the past decade, less than 30% of individuals on MDI therapy using a CGM achieve glycemic targets — highlighting a significant unmet need. We're excited to help more people to reach their goals with our advanced algorithm in InPen™ powered by our smallest and most comfortable CGM to-date," said Que Dallara, EVP and President, Medtronic Diabetes. Simplera is indicated for ages 2+ and is not approved by the FDA. Medtronic's automated insulin delivery (AID) system integrated with this next-generation sensor is currently under review for CE Mark and is not commercially available in the U.S. or in Europe.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 22,2023

Abbott Completes Acquisition of Bigfoot Biomedical

Abbott today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes. Pursuant to the terms of the merger agreement, upon completion of the acquisition, Bigfoot became a wholly owned subsidiary of Abbott. Financial terms were not disclosed.

View Analyst & Ambassador Comments
Go to original news
Jan 14,2022

A 12-Month Follow-Up of the Effects of a Digital Diabetes Prevention Program (VP Transform for Prediabetes) on Weight and Physical Activity Among Adults With Prediabetes: Secondary Analysis

The aim of this study is to investigate the effects of a digital Ddiabetes Prevention Program (DPP) (Virgin Pulse [VP] Transform for Prediabetes) on weight and physical activity among participants who had completed 12 months of the program. This study was a secondary analysis of retrospective data of adults with prediabetes who were enrolled in VP Transform for Prediabetes for 12 months of the program. The program incorporates interactive mobile computing, remote monitoring, an evidence-based curriculum, behavior tracking tools, health coaching, and online peer support to prevent or delay the onset of type 2 diabetes. The sample (N=1095) was comprised of people with prediabetes who completed at least 9 months of the VP Transform for Prediabetes program. The results suggest that VP Transform for Prediabetes is effective at preventing type 2 diabetes through a significant reduction in body weight and increase of physical activity. Furthermore, these results suggest that the DPP remains effective 12 months after beginning the program. 

CLINICAL STUDY

#coaching

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Sep 20,2023

Virgin Pulse Unveils Integrated Digital Therapeutics Suite to Rein in High-Cost Chronic Conditions

Virgin Pulse, the global wellbeing, and navigation company, is expanding its clinical health support with the new VP Transform, a suite of digital therapeutics solutions to proactively address chronic conditions, beginning with prediabetes, blood pressure, and weight management. The new VP Transform is a year-long, evidence-based, behavior change program embedded into the Homebase for Health platform, provided to employers and their people. VP Transform will focus on helping members achieve a clinically significant, sustainable weight while increasing levels of physical activity through a scalable digital therapeutic solution that's already part of their daily wellbeing routine. The company is contracting now for the new suite of solutions, which will be generally available in early 2024 and will initially provide support for prediabetes, weight management, and blood pressure.

PRODUCT

#coaching

#virtual care

View Analyst & Ambassador Comments
Go to original news
Aug 11,2023

Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study

This study explored the impact of switching to hybrid closed-loop (HCL) insulin delivery systems in adults with type 1 diabetes who had elevated HbA1c levels despite using intermittently scanned continuous glucose monitoring (isCGM) and insulin pump therapy. They conducted an observational study involving 570 HCL users across 31 diabetes centers in England. This study demonstrates that HCL insulin delivery systems can lead to significant improvements in glycemic control, reduced hypoglycemia, enhanced quality of life, and high patient satisfaction among adults with type 1 diabetes, even in real-world settings. The results showed significant improvements, including: The mean adjusted HbA1c decreased by 1.7% after switching to HCL, and TIR (glucose levels between 70–180 mg/dL) increased from 34.2% to 61.9%.

CLINICAL STUDY

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Aug 10,2023

Real-world Accuracy of CGM in Inpatient Critical and Noncritical Care Settings at a Safety-Net Hospital

The study aimed to assess the real-world accuracy of inpatient continuous glucose monitoring (CGM) at various levels of patient acuity in a large safety-net hospital. The research involved analyzing data from hospitalized patients who used Dexcom G6 CGM devices, comparing CGM glucose readings with both point of care (POC) and laboratory (Lab) glucose measurements. The patients were categorized as not critically ill (NCI) or critically ill (CI). The study found that CGM accuracy was acceptable in both NCI and CI patients, with the accuracy being slightly better when compared to Lab glucose readings than POC readings. The analysis also revealed that certain unique patient conditions, such as anorexia nervosa, hypoglycemia disorders, and specific medical interventions, could affect CGM accuracy. Overall, the study suggests that inpatient CGM can be a valuable tool for glucose management, especially when used in a critical care setting, but further research is needed to explore its limitations and benefits in real-world scenarios.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 20,2023

Artificial Intelligence and Diabetic Retinopathy: AI Framework, Prospective Studies, Head-to-head Validation, and Cost-effectiveness

The article titled "Artificial Intelligence and Diabetic Retinopathy" discusses the significant role of artificial intelligence (AI) algorithms in screening for diabetic retinopathy (DR), a leading cause of blindness in diabetic patients. It outlines the increasing global prevalence of diabetes and the imperative need for regular DR screenings. AI algorithms have been developed to autonomously analyze fundus photographs for signs of DR, achieving good sensitivity and specificity in detecting referable DR cases. The article explains the fundamental concepts of AI model development, data labeling, and training. Additionally, the article touches on the cost-effectiveness, equity, bias, and medicolegal considerations associated with AI implementation in clinical practice.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Sep 18,2023

ViCentra to Present at Emerging Medtech Summit Europe 2023

ViCentra B.V., the company behind Kaleido, one of the world’s smallest Insulin Pump systems for treating people with Diabetes, today announced that Frans Cromme, CEO will provide a corporate update at the Emerging Medtech Summit Europe taking place in Barcelona, Spain, September 18 to 22, 2023.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 18,2023

Insulin Pumps Market to Reach USD 12.0 Billion in 2032 Owing to Rising Prevalence of Diabetes and Advancements in Insulin Pumps

Global insulin pumps market size was USD 5.3 Billion in 2022 and is expected to reach USD 12.0 billion in 2032 and register a revenue CAGR of 8.7% between 2023 and 2032, according to the research publisher. It is estimated that 63% of adults with T1D in the US and 5–15% of those in Europe use an insulin pump.

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES